Combination chemo may be effective against myelodysplastic syndrome

chemo treatment NCI.jpg

A very small phase I study from researchers at the Cleveland Clinic's Taussig Cancer Institute suggests that there may be some future justification to using combination chemotherapy to treat myelodysplastic syndrome (MDS).

Currently there are three FDA-approved drugs to treat MDS and, unlike in other chemotherapy regimens, treatment guidelines call for the use of only one. This study examined the efficacy and toxicity of combining two into a single treatment.

BLOOD CANCER SUBTYPE(S) IN QUESTION

High-risk myelodysplastic syndrome

COHORT

Patients: 18
Median age: 68

RESEARCH FINDINGS

The combination of lenalidomide (Revlimid) and azacitidine (Vidaza) produced a response in 12 patients (67%) and a complete response in 8 (44%). The median duration of response was eight months. Eight of the responsive patients either relapsed or had their disease progress, with two progressing into acute myeloid leukemia (AML).

PUBLICATION & SOURCES

This study was published online in the Journal of Clinical Oncology .

By Ross Bonander

Source: MedPageToday

LymphomaInfo Social